{
  "docId": "019de071-753f-7227-aa1d-36a319c59353",
  "docSlug": "7013d0966bfedd0d757b9fa24a480455",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 34,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Clinical trial design diagram showing randomization between T-DXd and T-DM1.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/9",
  "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353",
  "deckJsonHref": "/decks/019de071-753f-7227-aa1d-36a319c59353.json",
  "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.94,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Randomization flow from patients to treatment arms",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6432ee17-c1c3-46fa-a6fd-59f21e68baff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.94,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Patients, Stratification factors, Endpoints",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acf760d8-7960-41db-9aaf-ae113a6d7c1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Interim analysis for PFS (data cutoff: May 21, 2021) Efficacy boundary for superiority: P < 0.000204 (based on 245 events) IDMC recommendation to unblind study (July 30, 2021)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb262029-4c66-4cd4-b595-037b8e997230",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "T-DXd, trastuzumab deruxtecan; T-DM1, ado-trastuzumab emtansine; BICR, blinded independent central review; DOR, duration of response; HER2, human epidermal growth factor receptor 2; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; Q3W, every 3 weeks.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a64b737-0252-41d2-8214-1cebd60f386c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "DESTINY-Breast03: first randomised phase III trial of T-DXd",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38bcfb77-be4c-4e61-a8fe-9680671e22a5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "7d6fc11c-9c63-4d02-bc07-8fe706170a68",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Detailed data on Enhertu's efficacy and safety",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f6f774ca-af54-4b25-aa3a-3b940b789d31",
      "evidence": "The deck highlights the limitations of current treatments and Enhertu's potential to improve patient outcomes.",
      "position": 0,
      "objective": "What are the consequences of not adopting Enhertu as the standard of care?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 14,
      "from": 9,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "4c136f41-d14c-4c9d-b4d4-01b2328be5bb",
      "evidence": "The deck presents detailed trial data to support Enhertu's efficacy and safety.",
      "position": 1,
      "objective": "How does Enhertu's data support its potential as a standard of care?",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.7,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}